Incidental Adrenal Mass
Walk the decision tree step by step, see it as a flowchart, or view the whole algorithm at once.
ACR IFC 2017·reviewed 2026-10-01
- •Applies to adults (≥18 years) with an asymptomatic adrenal mass ≥1 cm found on CT or MRI done for an unrelated reason. Assess bilateral masses separately. A mass <1 cm in short axis need not be pursued.
- •Consider biochemical evaluation for most incidental adrenal masses, and always exclude pheochromocytoma (plasma metanephrines) before biopsy or resection. The 2017 paper widened this from the 2010 advice, which tested only hypertensive or symptomatic patients.
- •Adrenal CT protocol: unenhanced 3 mm acquisition read in real time; if >10 HU, contrast-enhanced (60–90 s) and 15-min delayed images. Absolute washout = (enhanced − delayed)/(enhanced − unenhanced) × 100, ≥60% = adenoma. Relative washout = (enhanced − delayed)/enhanced × 100, ≥40% = adenoma. Chemical-shift MRI may be used instead.
- •Avid enhancement (>110–120 HU) should raise pheochromocytoma; recommend biochemical evaluation.
- •Workup may be unnecessary when it would not change management — for example, with multiple metastases elsewhere or limited life expectancy.
Does the mass have diagnostic benign imaging features?
Macroscopic fat (myelolipoma); no enhancement (<10 HU change between unenhanced and enhanced images — cyst or hemorrhage); benign calcification; unenhanced attenuation ≤10 HU or signal loss on chemical-shift MRI (lipid-rich adenoma).
Tip: press 1–2 to choose, Backspace to go back.
Sources
- Mayo-Smith WW, et al. Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017;14(8):1038-1044.source
Educational reference for clinicians — not medical advice. Verify against the primary source before acting on it; guidelines change. Final decisions rest with the interpreting physician and your institution's protocols.